
The UK Government has sealed another deal to procure an effective COVID-19 vaccine for its citizens, partnering up with Sanofi …

Roche has announced the disappointing news that its therapy Actemra/RoActemra (tocilizumab) failed to improve clinical status to a statistically significant …

Biopharma firm AI Therapeutics is partnering with Yale School of Medicine to launch a new clinical trial to identify the efficacy …

The subcutaneous (SC) formulation of Remsima, Celltrion’s biosimilar version of infliximab, has secured approval from the European Commission covering five …

AstraZeneca and Daiichi Sankyo have joined forces to drive the development and commercialisation of the latter’s DS-1062, a trophoblast cell-surface …

UCB has revealed promising new data from a head-to-head trial pitting the company’s IL-17A and IL-17F inhibitor bimekizumab against Novartis’ …

BioNTech and Pfizer have revealed more promising early data on their lipid nanoparticle formulated, nucleoside-modified messenger RNA vaccine candidate against …

AbbVie has lifted the curtain on data from the second Phase 3 trial investigating the efficacy of Rinvoq (upadacitinib) monotherapy …

Adoption of sustainable practices in pharmaceutical operations is ticking along, but given the environmental and health risks if this is …

The COVID-19 pandemic forced industries across the board to evolve or die with regard to their approach to digital working …

The FDA’s Oncologic Drugs Advisory Committee (ODAC) has moved to recommend the use of GlaxoSmithKline’s belantamab mafodotin, or GSK2857916 as …

Specialist tropical disease drug firm 60 Degrees Pharmaceuticals has revealed that its therapy Arakoda (tafenoquine) has been shown in cell …

Over 20 biopharma firms have come together to launch the AMR Action Fund, an initiative of the International Federation of …

In the latest chapter in Johnson & Johnson’s talc-related woes, the company is being pressured by group of over 170 …

Takeda has linked up with Carmine Therapeutics in a new partnership to discover, develop and bring to market new non-viral …